Top

Published in:

01-10-2020 | Pharmacokinetics | PHASE I STUDIES

A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

Authors: Sagar Sardesai, Mohamed Badawi, Ewa Mrozek, Evan Morgan, Mitch Phelps, Julie Stephens, Lai Wei, Mahmoud Kassem, Yonghua Ling, Maryam Lustberg, Daniel Stover, Nicole Williams, Rachel Layman, Raquel Reinbolt, Jeffrey VanDeusen, Mathew Cherian, Michael Grever, William Carson, Bhuvaneswari Ramaswamy, Robert Wesolowski

Published in: Investigational New Drugs | Issue 5/2020

Summary

Upregulation of Notch pathway is associated with poor prognosis in breast cancer. We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097. Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment. Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80 mg/m2 IV and RO4929097 10 mg daily given orally (PO) on days 1–3, 8–10 and 15–17 for six 21-day cycles. RO4929097 was escalated in 10 mg increments using the 3 + 3 dose escalation design. Two DLTs were observed in 14 patients - Grade (G) 4 thrombocytopenia in dose level 1 (10 mg) and G3 hypertension in dose level 2 (20 mg). Protocol-defined MTD was not determined due to discontinuation of RO4929097 development. However, 4 of 5 patients enrolled to 20 mg dose of RO4929097 required dose reduction to 10 mg due to toxicities (including neutropenia, thrombocytopenia and hypertension) occurring during and beyond the DLT observation period. Thus, 10 mg would have been the likely dose level for further development. G3 or higher hematologic toxicities included neutropenia (N = 8, 57%) and thrombocytopenia (N = 5, 36%) patients. Six (43%) patients had G2–3 neuropathy requiring paclitaxel dose reduction. No signs of drug-drug interaction between paclitaxel and RO4929097 were evident. Five patients (36%) had pCR.

Available only for authorised users

Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast Cancer. N Engl J Med 363:1938–1948. https://doi.org/10.1056/NEJMra1001389CrossRefPubMed

Anders CK, Zagar TM, Carey LA (2013) The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer. Hematol Oncol Clin North Am 27:737–749. https://doi.org/10.1016/j.hoc.2013.05.003CrossRefPubMedPubMedCentral

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast Cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045CrossRefPubMed

Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive Cancer network. Cancer 118:5463–5472. https://doi.org/10.1002/cncr.27581CrossRefPubMed

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Trial Investigators (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer. N Engl J Med 379:2108–2121. https://doi.org/10.1056/NEJMoa1809615CrossRefPubMed

Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRefPubMed

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:753–763CrossRefPubMed

Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast Cancer: improving patient selection for treatment. Cancer Discovery 9:176–198. https://doi.org/10.1158/2159-8290.CD-18-1177CrossRefPubMedPubMedCentral

Bardia A, Baselga J (2013) Neoadjuvant therapy as a platform for drug development and approval in breast Cancer. Clin Cancer Res 19:6360–6370. https://doi.org/10.1158/1078-0432.CCR-13-0916CrossRefPubMed

10.

Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32. https://doi.org/10.1016/S1470-2045(11)70336-9CrossRefPubMed

11.

Gianni L, Pienkowski T, Im Y-H, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17:791–800. https://doi.org/10.1016/S1470-2045(16)00163-7CrossRefPubMed

12.

Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, de Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE (2010) Efficacy of Neoadjuvant Cisplatin in triple-negative breast Cancer. J Clin Oncol 28:1145–1153. https://doi.org/10.1200/JCO.2009.22.4725CrossRefPubMedPubMedCentral

13.

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP (2015) Impact of the addition of carboplatin and/or Bevacizumab to Neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast Cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13–21. https://doi.org/10.1200/JCO.2014.57.0572CrossRefPubMed

14.

von Minckwitz G, Schneeweiss A, Loibl S et al (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747–756. https://doi.org/10.1016/S1470-2045(14)70160-3CrossRef

15.

Lee CW, Raskett CM, Prudovsky I, Altieri DC (2008) Molecular dependence of estrogen receptor-negative breast Cancer on a notch-Survivin signaling Axis. Cancer Res 68:5273–5281. https://doi.org/10.1158/0008-5472.CAN-07-6673CrossRefPubMedPubMedCentral

16.

Izrailit J, Reedijk M (2012) Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications. Cancer Lett 317:115–126. https://doi.org/10.1016/j.canlet.2011.11.028CrossRefPubMed

17.

Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, notch, and hedgehog pathways. Nat Rev Clin Oncol 8:97–106. https://doi.org/10.1038/nrclinonc.2010.196CrossRefPubMed

18.

Dontu G, Jackson KW, McNicholas E et al (2004) Role of notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 6. https://doi.org/10.1186/bcr920

19.

Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE (2010) Inhibition of notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 30:3853–3867PubMed

20.

Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymer I, Lippincott J, Zachwieja J, Gajiwala K, Kraynov E, Thibault S, Stone D, Gao Y, Sofia S, Gallo J, Li G, Yang J, Li K, Wei P (2013) Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett 328:261–270. https://doi.org/10.1016/j.canlet.2012.09.023CrossRefPubMed

21.

Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready D, Lockwood G, Egan SE (2005) High-level Coexpression of JAG1 and NOTCH1 is observed in human breast Cancer and is associated with poor overall survival. Cancer Res 65:8530–8537. https://doi.org/10.1158/0008-5472.CAN-05-1069CrossRefPubMed

22.

Yamaguchi N, Oyama T, Ito E, Satoh H, Azuma S, Hayashi M, Shimizu K, Honma R, Yanagisawa Y, Nishikawa A, Kawamura M, Imai J, Ohwada S, Tatsuta K, Inoue J, Semba K, Watanabe S (2008) NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast Cancer cells. Cancer Res 68:1881–1888. https://doi.org/10.1158/0008-5472.CAN-07-1597CrossRefPubMed

23.

Mumm JS, Kopan R (2000) Notch signaling: from the outside in. Dev Biol 228:151–165. https://doi.org/10.1006/dbio.2000.9960CrossRefPubMed

24.

Osipo C, Zlobin O-K (2013) Gamma secretase inhibitors of notch signaling. OncoTargets Ther 943. https://doi.org/10.2147/OTT.S33766

25.

Locatelli MA, Aftimos P, Dees EC, et al (2017) Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. Oncotarget 8:. https://doi.org/10.18632/oncotarget.13727

26.

Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E (2014) A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investig New Drugs 32:243–249. https://doi.org/10.1007/s10637-013-9965-4CrossRef

27.

Massard C, Azaro A, Soria J-C, Lassen U, le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J (2018) First-in-human study of LY3039478, an oral notch signaling inhibitor in advanced or metastatic cancer. Ann Oncol 29:1911–1917. https://doi.org/10.1093/annonc/mdy244CrossRefPubMed

28.

Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC (2013) Preclinical and clinical studies of gamma Secretase inhibitors with Docetaxel on human breast tumors. Clin Cancer Res 19:1512–1524. https://doi.org/10.1158/1078-0432.CCR-11-3326CrossRefPubMedPubMedCentral

29.

Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ (2012) Phase I study of RO4929097, a gamma Secretase inhibitor of notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30:2348–2353. https://doi.org/10.1200/JCO.2011.36.8282CrossRefPubMedPubMedCentral

30.

De Jesus-Acosta A, Laheru D, Maitra A et al (2014) A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Investig New Drugs 32:739–745. https://doi.org/10.1007/s10637-014-0083-8CrossRef

31.

Sahebjam S, Bedard PL, Castonguay V, Chen Z, Reedijk M, Liu G, Cohen B, Zhang WJ, Clarke B, Zhang T, Kamel-Reid S, Chen H, Ivy SP, Razak AR, Oza AM, Chen EX, Hirte HW, McGarrity A, Wang L, Siu LL, Hotte SJ (2013) A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). Br J Cancer 109:943–949. https://doi.org/10.1038/bjc.2013.380CrossRefPubMedPubMedCentral

32.

Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, Singh A, Khiabanian H, Pine SR (2017) Gamma Secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma. Mol Cancer Ther 16:2759–2769. https://doi.org/10.1158/1535-7163.MCT-17-0439CrossRefPubMedPubMedCentral

33.

LoConte NK, Razak ARA, Ivy P, Tevaarwerk A, Leverence R, Kolesar J, Siu L, Lubner SJ, Mulkerin DL, Schelman WR, Deming DA, Holen KD, Carmichael L, Eickhoff J, Liu G (2015) A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investig New Drugs 33:169–176. https://doi.org/10.1007/s10637-014-0166-6CrossRef

34.

Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933: RO4929097 in melanoma: SWOG 0933. Cancer 121:432–440. https://doi.org/10.1002/cncr.29055CrossRefPubMed

35.

Loibl S, O’Shaughnessy J, Untch M et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19:497–509. https://doi.org/10.1016/S1470-2045(18)30111-6CrossRefPubMed

36.

Krop IE, Kosh M, Fearen I et al (2006) Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol 24:10574–10574. https://doi.org/10.1200/jco.2006.24.18_suppl.10574CrossRef

37.

Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, Gass JS, Kennedy TA, Fenton MA (2009) Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University oncology group study. J Clin Oncol 27:4693–4700. https://doi.org/10.1200/JCO.2008.21.4163CrossRefPubMed

38.

Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor CS, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D, Márquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGinness M, Klemp JR, Amin AL, Fabian CJ, Heldstab J, Godwin AK, Jensen RA, Kimler BF, Khan QJ, Martin M (2017) Efficacy of Neoadjuvant carboplatin plus Docetaxel in triple-negative breast Cancer: combined analysis of two cohorts. Clin Cancer Res 23:649–657. https://doi.org/10.1158/1078-0432.CCR-16-0162CrossRefPubMed

39.

Ramaswamy B, Mrozek E, Lustberg M, et al (2016) Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer. Cancer Res 76:LB-216. https://doi.org/10.1158/1538-7445.AM2016-LB-216

Title: A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer
Authors: Sagar Sardesai
Mohamed Badawi
Ewa Mrozek
Evan Morgan
Mitch Phelps
Julie Stephens
Lai Wei
Mahmoud Kassem
Yonghua Ling
Maryam Lustberg
Daniel Stover
Nicole Williams
Rachel Layman
Raquel Reinbolt
Jeffrey VanDeusen
Mathew Cherian
Michael Grever
William Carson
Bhuvaneswari Ramaswamy
Robert Wesolowski
Publication date: 01-10-2020
Publisher: Springer US
Keywords: Pharmacokinetics
Breast Cancer
Neutropenia
Breast Cancer
Thrombocytopenia
Cytostatic Therapy
Published in: Investigational New Drugs / Issue 5/2020
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-020-00895-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2020

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

W941, a new PI3K inhibitor, exhibits preferable anti-proliferative activities against nonsmall cell lung cancer with autophagy inhibitors

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer